Coumadin, Warfarin News

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted against a new use of a new blood thinner, Xarelto, to cut the risk of potentially lethal clots in people with acute coronary syndrome. The panel of experts voted 6-to-4, with one member abstaining, against using the drug in these high-risk patients.

After suffering a type of blood clot called a venous thromboembolism, patients usually take a blood-thinner such as warfarin .

There's only one really bad thing about the anti-clotting pill Pradaxa. You can't fall or get cut while taking it because once you start bleeding, there's almost no way to stop it.

The new blood thinner Xarelto appears to lower the chances of potentially fatal blood clots in high-risk heart patients, a U.S. Food and Drug Administration review has found. The review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome .

This example of a disaster waiting to happen, in the form of an error-promoting CPOE, is a poster example of why the net of litigation needs to be cast far wider than just clinicians when EHR-related errors result in injury or death.

Independent developer James Hollender is conducting a Mothers Day Weekend Sale on all his iNutrient universal apps for the iPad, iPhone and iPod touch: iCals , iCarbs , iCholesterol , iFiber , iProtein , iSatFat , iSugars , and Vitamin K . All of these apps, based on USDA National Nutrient DB were recently upgraded to be universal ; and also ... (more)

A 10-year multi-center study found that aspirin and the blood thinner warfarin were equally effective at preventing a combined risk of death, stroke, and cerebral hemorrhage in heart failure patients with normal heart rhythm.

The drug warfarin is no better than aspirin in reducing the risks of brain hemorrhage, stroke and death in most heart failure patients, U.S. researchers say.

Older women with the irregular heartbeat known as atrial fibrillation face a 14 percent greater risk of stroke than men with the same condition, Canadian researchers report. The raised risk remained higher even when women were taking the blood-thinner warfarin to prevent stroke, the study authors noted.

The makers of the popular anti-nausea drug Gravol have come out with a new product, called Gravol Multi-Symptom , which promises to relieve headaches and fever as well as stave off nausea, all with ingredients from natural sources.

The combined risk of death, stroke, and cerebral hemorrhage was 7.47 percent per year for patients taking warfarin, and 7.93 percent per year for those taking aspirin, a difference that researchers said was not statistically significant.

Pharmacy's across Texoma are dealing with prescription drug price hikes. We took a look at pill pricing in some pharmacy's in Wichita Falls to see how they price their drugs, and if they are looking out for you the consumer.

WALTHAM, Mass. -- -- Today, at the 2012 Thrombosis and Hemostasis Summit of North America, Alere Inc.

Neither aspirin nor warfarin is superior for preventing a combined risk of death, stroke, and cerebral hemorrhage in heart failure patients with normal heart rhythm, according to a landmark clinical trial published in the New England Journal of Medicine.

Aspirin and warfarin are equally effective in preventing strokes and death for many people with heart failure, a new study finds.

A Lehigh Valley Hospital doctor co-authored a landmark study published today that aspirin and warfarin are equally effective for preventing a combined risk of death, stroke and cerebral hemorrhage in heart failure patients.

Results of one of the largest studies of heart failure to date show that warfarin is no better than aspirin in reducing the combined risks of brain hemorrhage, stroke and death in most heart failure patients.

Neither aspirin nor warfarin is superior for preventing a combined risk of death, stroke, and cerebral hemorrhage in heart failure patients with normal heart rhythm, according to a landmark clinical trial published in today's New England Journal of Medicine .